Amputations among U.S. patients with diabetes decreased between 2000 and 2009 but increased by 50% from 2009 to 2015, leading the American Heart Association (AHA) to call for better identification and treatment of peripheral artery disease and propose policy solutions.
9 Apr 2021
A recent meta-analysis from Denmark looked at patients with genetic variations that cause increases in plasma glucose levels and found that their elevated ischemic stroke risk appeared to be mitigated by treatment with certain classes of diabetes drugs.
9 Apr 2021
A study used simulation modeling to project the long-term effects of a three-month exercise and cognitive behavioral therapy (CBT) intervention for patients with type 2 diabetes and major depressive disorder. It found clear cost-effectiveness with the interventions alone or combined.
12 Mar 2021
A retrospective study found that new users of sodium-glucose cotransporter-2 (SGLT-2) inhibitors developed diabetic ketoacidosis at a rate of about 6 per 1,000 person-years, compared to 4.3 or 4.5 per 1,000 person-years with dipeptidyl peptidase-4 (DPP-4) inhibitors or sulfonylureas, respectively.
11 Mar 2022
The kidney group's guideline supports metformin and sodium–glucose cotransporter-2 inhibitors as first-line therapies for patients with chronic kidney disease (CKD) based on consistent trial data showing their effectiveness, noted an ACP Journal Club commentary.
12 Mar 2021
An industry-sponsored phase 3 trial found statistically significant improvements in HbA1c level among patients with type 2 diabetes who had inadequate glycemic control on insulin glargine and were randomly assigned to subcutaneous tirzepatide once weekly versus placebo.
11 Feb 2022
Studies find link between metformin and reduced COVID-19 mortality, mixed results for DPP-4 inhibitors
Prior metformin use was associated with a threefold decrease in mortality from COVID-19 in one study of patients with type 2 diabetes, while three other studies found mixed results on whether dipeptidyl peptidase-4 (DPP-4) inhibitors affect COVID-19 outcomes.
12 Feb 2021
The updated guideline from the American Academy of Neurology supports offering tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, gabapentinoids, and/or sodium channel blockers to reduce pain from diabetic neuropathy.
14 Jan 2022
The score, which was based on cardiac troponin, N-terminal pro-B-type natriuretic peptide, C-reactive protein, and electrocardiography, could be used to target specific therapies to the highest-risk patients, study authors said.
8 Jan 2021
Risk factor control was more strongly associated with mortality risk among patients with cardiorenal disease than those without, according to a retrospective British study.
11 Dec 2020